ArticleFrontiers in neurology2024

Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

Stephan Ortiz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.